{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T21:05:27Z","timestamp":1779829527694,"version":"3.53.1"},"reference-count":116,"publisher":"Begell House","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2026]]},"abstract":"<p>Type I interferons (IFN-I) exert a significant influence on the immune system. Produced by certain immune cells, they affect other immune cells and mediate diverse effects, including antiviral activity, inhibition of tumor growth, and suppression of cell proliferation. IFN-I is also implicated in the development and persistence of autoimmune\ndisorders. Research has shown that abnormal IFN-I levels and IFN-I-regulated gene expression in the blood or tissues\nof individuals with autoimmune diseases are associated with disease onset, clinical manifestations, and severity. Monogenic conditions known as Type I interferonopathies-caused by mutations affecting the IFN-I signaling pathway-share clinical features with systemic lupus erythematosus (SLE). Both preclinical models and clinical trials targeting the IFN-I signaling pathway have yielded promising results for the treatment of autoimmune diseases. This review provides an overview of the interplay between epigenetics, various types of RNAs, transcription factors, and IFN-I. It discusses epigenetic modifications and transcription factor dysregulation, offering insights into disease mechanisms and potential future therapeutic advancements.<\/p>","DOI":"10.1615\/critrevimmunol.2026062673","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:21:54Z","timestamp":1776975714000},"page":"77-95","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging Type I Interferons: Exploring Pathogenesis and Therapeutic Strategies in Autoimmune Diseases"],"prefix":"10.1615","volume":"46","author":[{"given":"Sarvin","family":"Jabbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Safaralizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira Aboutalebi Vand","family":"Beilankouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Valilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadali","family":"Hosseinpourfeizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Baradaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Khodavirdipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Hemmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-\u0080\u0094Elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-\u0080\u009325.","DOI":"10.1016\/j.coi.2014.01.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Vacchelli E, Aranda F, Bloy N, Buqu\u00e9 A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch-\u0080\u0094Immunostimulation with cytokines in cancer therapy. OncoImmunology. 2016;5(2):e1115942.","DOI":"10.1080\/2162402X.2015.1115942"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY. An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 2019;35(1):33-\u0080\u009345.e6.","DOI":"10.1016\/j.ccell.2018.12.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chen W, Wu Y, Deng J, Yang Z, Chen J, Tan Q, Guo M, Jin Y. Phospholipid-membrane-based nanovesicles acting as vaccines for tumor immunotherapy: Classification, mechanisms and applications. Pharmaceutics. 2022;14(11):2446.","DOI":"10.3390\/pharmaceutics14112446"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Negishi H, Taniguchi T, Yanai H. The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family. Cold Spring Harb Perspect Biol. 2018;10(11):a028423.","DOI":"10.1101\/cshperspect.a028423"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Seeds RE, Miller JL. Measurement of Type I interferon production. Curr Protoc Immunol. 2011;Chapter 14:Unit14.21.1-11.","DOI":"10.1002\/0471142735.im1421s92"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Soleimani Mamalo A, Pashaei M, Valilo M, Ojarudi M. Cytokine-mediated regulation of immune cell metabolic pathways in the tumor microenvironment. Naunyn-Schmiedeberg's Arch Pharmacol. 2025;398(9):11783-\u0080\u0093801.","DOI":"10.1007\/s00210-025-04133-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Zhan Y, Chow KV, Soo P, Xu Z, Brady JL, Lawlor KE, Masters SL, O'keeffe M, Shortman K, Zhang JG, Lew AM. Plasmacytoid dendritic cells are short-lived: Reappraising the influence of migration, genetic factors and activation on estimation of lifespan. Sci Rep. 2016;6(1):25060.","DOI":"10.1038\/srep25060"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: Emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5(5):e79.","DOI":"10.1038\/cti.2016.26"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Jones SA, Morand EF. Targeting interferon signalling in systemic lupus erythematosus: Lessons learned. Drugs. 2024;84(6):625-\u0080\u009335.","DOI":"10.1007\/s40265-024-02043-2"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865-\u0080\u009375.","DOI":"10.1136\/annrheumdis-2020-219012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Zhao J, Xiao R, Zeng R, He E, Zhang A. Small molecules targeting cGAS-STING pathway for autoimmune disease. Eur J Med Chem. 2022;238:114480.","DOI":"10.1016\/j.ejmech.2022.114480"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Lama L, Adura C, Xie W, Tomita D, Kamei T, Kuryavyi V, Gogakos T, Steinberg JI, Miller M, Ramos-Espiritu L, Asano Y, Hashizume S, Aida J, Imaeda T, Okamoto R, Jennings AJ, Michino M, Kuroita T, Stamford A, Gao P, Meinke P, Glickman JF, Patel DJ, Tuschl T. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression. Nat Commun. 2019;10(1):2261.","DOI":"10.1038\/s41467-019-08620-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Wang S, Xie L, Xie Z, Wan L, Huang J, Deng X, Xie Z qin, Luo S, Zeng T, Zhang Y, Zhang M, Zhou L. Dynamic changes in the expression of interferon-stimulated genes in joints of SPF chickens infected with avian reovirus. Front Vet Sci. 2021;8.","DOI":"10.3389\/fvets.2021.618124"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Eberhardt N, Bergero G, Mazzocco Mariotta YL, Aoki MP. Purinergic modulation of the immune response to infections. Purinergic Signal. 2022;18(1):93-\u0080\u0093113.","DOI":"10.1007\/s11302-021-09838-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Miyake K, Shibata T, Ohto U, Shimizu T, Saitoh SI, Fukui R, Murakami Y. Mechanisms controlling nucleic acid-sensing Toll-like receptors. Int Immunol. 2018;30(2):43-\u0080\u009351.","DOI":"10.1093\/intimm\/dxy016"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Reizis B. Plasmacytoid dendritic cells: Development, regulation, and function. Immunity. 2019;50(1):37-\u0080\u009350.","DOI":"10.1016\/j.immuni.2018.12.027"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20(12):1574-\u0080\u009383.","DOI":"10.1038\/s41590-019-0466-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Cheng Y, Zhu W, Ding C, Niu Q, Wang H, Yan Y, Sun J. IRF7 is involved in both STING and MAVS mediating IFN-\u03b2 signaling in IRF3-lacking chickens. J Immunol. 2019;203(7):1930-\u0080\u009342.","DOI":"10.4049\/jimmunol.1900293"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Vidya MK, Kumar VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol. 2018;37(1):20-\u0080\u009336.","DOI":"10.1080\/08830185.2017.1380200"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Ali S, Mann-N\u00fcttel R, Schulze A, Richter L, Alferink J, Scheu S. Sources of Type I interferons in infectious immunity: Plasmacytoid dendritic cells not always in the driver\u2019s seat. Front Immunol. 2019;10:778.","DOI":"10.3389\/fimmu.2019.00778"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Ivashkiv LB. IFN\u03b3: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545-\u0080\u009358.","DOI":"10.1038\/s41577-018-0029-z"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Hermant C, Torres-Padilla ME. TFs for TEs: The transcription factor repertoire of mammalian transposable elements. Genes Dev. 2021;35(1-2):22-\u0080\u009339.","DOI":"10.1101\/gad.344473.120"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Fueyo R, Judd J, Feschotte C, Wysocka J. Roles of transposable elements in the regulation of mammalian transcription. Nat Rev Mol Cell Biol. 2022;23(7):481-\u0080\u009397.","DOI":"10.1038\/s41580-022-00457-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Enriquez-Gasca R, Gould PA, Rowe HM. Host gene regulation by transposable elements: The new, the old and the ugly. Viruses. 2020;12(10):1089.","DOI":"10.3390\/v12101089"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Chuong EB, Elde NC, Feschotte C. Regulatory activities of transposable elements: From conflicts to benefits. Nat Rev Genet. 2017;18(2):71-\u0080\u009386.","DOI":"10.1038\/nrg.2016.139"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Jiang Z, Hsu JL, Li Y, Hortobagyi GN, Hung MC. Cancer cell metabolism bolsters immunotherapy resistance by promoting an immunosuppressive tumor microenvironment. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.01197"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Singleton DC, Macann A, Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. Nat Rev Clin Oncol. 2021;18(12):751-\u0080\u009372.","DOI":"10.1038\/s41571-021-00539-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Tunbak H, Enriquez-Gasca R, Tie CHC, Gould PA, Mlcochova P, Gupta RK, Fernandes L, Holt J, van der Veen AG, Giampazolias E, Burns KH, Maillard PV, Rowe HM. The HUSH complex is a gatekeeper of Type I interferon through epigenetic regulation of LINE-1s. Nat Commun. 2020;11(1):5387.","DOI":"10.1038\/s41467-020-19170-5"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Zinad HS, Natasya I, Werner A. Natural antisense transcripts at the interface between host genome and mobile genetic elements. Front Microbiol. 2017;8:2292.","DOI":"10.3389\/fmicb.2017.02292"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Chen K, Liu J, Cao X. Regulation of Type I interferon signaling in immunity and inflammation: A comprehensive review. J Autoimmun. 2017;83:1-\u0080\u009311.","DOI":"10.1016\/j.jaut.2017.03.008"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Shemesh M, Lochte S, Piehler J, Schreiber G. IFNAR1 and IFNAR2 play distinct roles in initiating Type I interferon-\u0080\u0093induced JAK-STAT signaling and activating STATs. Sci Signal. 2021;14(710):eabe4627.","DOI":"10.1126\/scisignal.abe4627"},{"key":"33","unstructured":"Menetti V. Modulation of LINE-1 retrotransposition by Aicardi-Gouti\u00e8res syndrome-related genes [dissertation]. Milan, Italy: University of Milan; 2020."},{"key":"34","doi-asserted-by":"crossref","unstructured":"Raftery N, Stevenson NJ. Advances in anti-viral immune defence: Revealing the importance of the IFN JAK\/STAT pathway. Cell Mol Life Sci. 2017;74(14):2525-\u0080\u009335.","DOI":"10.1007\/s00018-017-2520-2"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Garelli CJ, Refat MA, Nanaware PP, Ramirez-Ortiz ZG, Rashighi M, Richmond JM. Current insights in cutaneous lupus erythematosus immunopathogenesis. Front Immunol. 2020;11.","DOI":"10.3389\/fimmu.2020.01353"},{"key":"36","unstructured":"Hu Y. Compounds that inhibit cytokine-induced interleukin-6 expression in a monocytic cell line [Internet]. Ohio University; 2015. Available from: http:\/\/rave.ohiolink.edu\/etdc\/view?acc_num=ohiou1420708103"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Dong M, Fitzgerald KA. DNA-sensing pathways in health, autoinflammatory and autoimmune diseases. Nat Immunol. 2024;25(11):2001-\u0080\u009314.","DOI":"10.1038\/s41590-024-01966-y"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Saeidi A, Zandi K, Cheok YY, Saeidi H, Wong WF, Lee CYQ, Cheong HC, Yong YK, Larsson M, Shankar EM. T-cell exhaustion in chronic infections: Reversing the state of exhaustion and reinvigorating optimal protective immune responses. Front Immunol. 2018; 9:2569","DOI":"10.3389\/fimmu.2018.02569"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Liu S, Liu X, Li J, Zhou H, Carr MJ, Zhang Z, Shi W. Long noncoding RNAs: Novel regulators of virus-host interactions. Rev Med Virol. 2019;29(4):e2046.","DOI":"10.1002\/rmv.2046"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, Blosser W, Gupta S, Stewart J, Webster Y, Dempsey J, VanWye AB, Ebert P, Iversen P, Olsen JB, Gong X, Buchanan S, Houghton P, Stancato L. Abemaciclib is active in preclinical models of Ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling. Clin Cancer Res. 2018;24(23):6028-\u0080\u009339.","DOI":"10.1158\/1078-0432.CCR-18-1256"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Arimoto KI, Miyauchi S, Stoner SA, Fan JB, Zhang DE. Negative regulation of Type I IFN signaling. J Leukocyte Biol. 2018;103(6):1099-\u0080\u0093116.","DOI":"10.1002\/JLB.2MIR0817-342R"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang Y, Yang G. Research progress in hepatitis B virus covalently closed circular DNA. Cancer Biol Med. 2022;19(4):415-\u0080\u009331.","DOI":"10.20892\/j.issn.2095-3941.2021.0454"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Tang JL, Yang Q, Xu CH, Zhao H, Liu YL, Liu CY, Zhou Y, Gai DW, Pei RJ, Wang Y, Hu X, Zhong B, Wang YY, Chen XW, Chen JZ. Histone deacetylase 3 promotes innate antiviral immunity through deacetylation of TBK1. Protein Cell. 2021;12(4):261-\u0080\u009378.","DOI":"10.1007\/s13238-020-00751-5"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Sohn SY, Hearing P. Adenoviral strategies to overcome innate cellular responses to infection. FEBS Lett. 2019;593(24):3484-\u0080\u009395.","DOI":"10.1002\/1873-3468.13680"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Amiri R, Nabi PN, Fazilat A, Roshani F, Nouhi Kararoudi A, Hemmati-Dinarvand M, Valilo M. Crosstalk between miRNAs and signaling pathways in the development of drug resistance in breast cancer. Horm Mol Biol Clin Investig. 2025;46(2):47-\u0080\u009355.","DOI":"10.1515\/hmbci-2024-0066"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Beilankouhi EAV, Maghsoodi MS, Sani MZ, Khosroshahi NS, Zarezadeh R, Nargesi MM, Safaralizadeh R, Valilo M. miRNAs that regulate apoptosis in breast cancer and cervical cancer. Cell Biochem Biophys. 2024;82(3):1993-\u0080\u00932006.","DOI":"10.1007\/s12013-024-01405-7"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Frasca F, Scordio M, Scagnolari C. Chapter 15 - MicroRNAs and the immune system. In: Xiao J, editor. MicroRNA [Internet]. Academic Press; 2022. p. 279-\u0080\u0093305.Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/B9780323897747000078","DOI":"10.1016\/B978-0-323-89774-7.00007-8"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Ji X, Meng W, Liu Z, Mu X. Emerging roles of lncRNAs regulating RNA-mediated Type-I interferon signaling pathway. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.811122"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Jia X, Tan L, Chen S, Tang R, Chen W. Monogenic lupus: Tracing the therapeutic implications from single gene mutations. Clin Immunol. 2023;254:109699.","DOI":"10.1016\/j.clim.2023.109699"},{"key":"50","unstructured":"Melki I. Clinical and molecular characterisation of Type I interferonopathies [dissertation]. Paris: Paris Descartes University; 2017."},{"key":"51","doi-asserted-by":"crossref","unstructured":"Quiros-Roldan E, Sottini A, Signorini SG, Serana F, Tiecco G, Imberti L. Autoantibodies to interferons in infectious diseases. Viruses. 2023;15(5):1215.","DOI":"10.3390\/v15051215"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Crow YJ, Stetson DB. The Type I interferonopathies: 10 years on. Nat Rev Immunol. 2022;22(8):471-\u0080\u009383.","DOI":"10.1038\/s41577-021-00633-9"},{"key":"53","doi-asserted-by":"crossref","unstructured":"de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: Disorders of amplified danger signaling. Annu Rev Immunol. 2015;33(1):823-\u0080\u009374.","DOI":"10.1146\/annurev-immunol-032414-112227"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Gregersen PK, Behrens TW. Genetics of autoimmune diseases-\u0080\u0094Disorders of immune homeostasis. Nat Rev Genet. 2006;7(12):917-\u0080\u009328.","DOI":"10.1038\/nrg1944"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Yuan J, Yin Z, Tan L, Zhu W, Tao K, Wang G, Shi W, Gao J. Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer. Cancer Lett. 2019;457:28-\u0080\u009339.","DOI":"10.1016\/j.canlet.2019.05.006"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer. Cancer Lett. 2018;418:211-\u0080\u009320.","DOI":"10.1016\/j.canlet.2018.01.031"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Yan Y, Zheng L, Du Q, Cui X, Dong K, Guo Y, Geller DA. Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells. Br J Cancer. 2021;125(1):101-\u0080\u009311.","DOI":"10.1038\/s41416-021-01337-6"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Tong M, Wang J, Jiang N, Pan H, Li D. Correlation between p-STAT3 overexpression and prognosis in lung cancer: A systematic review and meta-analysis. PLoS One. 2017;12(8):e0182282.","DOI":"10.1371\/journal.pone.0182282"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Koh YC, Ho CT, Pan MH. Recent advances in cancer chemoprevention with phytochemicals. J Food Drug Anal. 2020;28(1):14-\u0080\u009337.","DOI":"10.1016\/j.jfda.2019.11.001"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Lu X, Li R, Ying Y, Zhang W. A comprehensive analysis of interferon regulatory factor expression: Correlation with immune cell infiltration and patient prognosis in endometrial carcinoma. Biomed Res Int. 2022;2022:7948898.","DOI":"10.1155\/2022\/7948898"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Naseri Z, Kazemi Oskuee R, Jaafari MR, Forouzandeh M. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nanomed. 2018;13:7727-\u0080\u009347 .","DOI":"10.2147\/IJN.S182384"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Feng J, Wang M, Li M, Yang J, Jia J, Liu L, Zhou J, Zhang C, Wang X. Serum miR-221-3p as a new potential biomarker for depressed mood in perioperative patients. Brain Res. 2019;1720:146296.","DOI":"10.1016\/j.brainres.2019.06.015"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Li H, Chen X, Zhu Y, Liu R, Zheng L, Shan S, Zhang F, An L, Yang G. Molecular characterization and immune functional analysis of IRF2 in common carp (Cyprinus carpio L.): Different regulatory role in the IFN and NF-\u00ce\u00baB signalling pathway. BMC Vet Res. 2021;17(1):303.","DOI":"10.1186\/s12917-021-03012-7"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Chouri E, Wang M, Hillen MR, Angiolilli C, Silva-Cardoso SC, Wichers CGK, van der Kroef M, Bekker CPJ, Cossu M, van Bon L, Affandi AJ, Carvalheiro T, Pandit A, van Roon JAG, Beretta L, Burgering BMT, Radstake TRDJ, Rossato M. Implication of miR-126 and miR-139-5p in plasmacytoid dendritic cell dysregulation in systemic sclerosis. J Clin Med. 2021;10(3):491.","DOI":"10.3390\/jcm10030491"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Marroqui L, Perez-Serna AA, Babiloni-Chust I, Dos Santos RS. Type I interferons as key players in pancreatic \u00ce\u00b2-cell dysfunction in type 1 diabetes. Int Rev Cell Mol Biol. 2021;359:1-\u0080\u009380.","DOI":"10.1016\/bs.ircmb.2021.02.011"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Su YC, Huang YF, Wu YW, Chen HF, Wu YH, Hsu CC, Hsu YC, Lee JC. MicroRNA-155 inhibits dengue virus replication by inducing heme oxygenase-1-mediated antiviral interferon responses. FASEB J. 2020;34(6):7283-\u0080\u009394.","DOI":"10.1096\/fj.201902878R"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Arboleda JF, Fernandez GJ, Urcuqui-Inchima S. Vitamin D-mediated attenuation of miR-155 in human macrophages infected with dengue virus: Implications for the cytokine response. Infect Genet Evol. 2019;69:12-\u0080\u009321.","DOI":"10.1016\/j.meegid.2018.12.033"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Rehwinkel J, Gack MU. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20(9):537-\u0080\u009351.","DOI":"10.1038\/s41577-020-0288-3"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Navarro E, Funtikova AN, F\u00edto M, Schr\u00f6der H. Prenatal nutrition and the risk of adult obesity: Long-term effects of nutrition on epigenetic mechanisms regulating gene expression. J Nutr Biochem. 2017;39:1-\u0080\u009314.","DOI":"10.1016\/j.jnutbio.2016.03.012"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Valadkhan S, Fortes P. Regulation of the interferon response by lncRNAs in HCV infection. Front Microbiol. 2018;9.","DOI":"10.3389\/fmicb.2018.00181"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Friedman MJ, Lee H, Lee JY, Oh S. Transcriptional and epigenetic regulation of context-dependent plasticity in T-helper lineages. Immune Netw. 2023;23(1):e5.","DOI":"10.4110\/in.2023.23.e5"},{"key":"72","doi-asserted-by":"crossref","unstructured":"Valadkhan S, Gunawardane LS. lncRNA-mediated regulation of the interferon response. Virus Res. 2016;212:127-\u0080\u009336.","DOI":"10.1016\/j.virusres.2015.09.023"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Carpenter S, Aiello D, Atianand MK, Ricci EP, Gandhi P, Hall LL, Byron M, Monks B, Henry-Bezy M, Lawrence JB, O\u2019Neill LAJ, Moore MJ, Caffrey DR, Fitzgerald KA. A long noncoding RNA mediates both activation and repression of immune response genes. Science. 2013;341(6147):789-\u0080\u009392.","DOI":"10.1126\/science.1240925"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Han P, Chang CP. Long non-coding RNA and chromatin remodeling. RNA Biol. 2015;12(10):1094.","DOI":"10.1080\/15476286.2015.1063770"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Zarkou V, Galaras A, Giakountis A, Hatzis P. Crosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs. Noncoding RNA Res. 2018;3(2):42-\u0080\u009353.","DOI":"10.1016\/j.ncrna.2018.04.001"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Suarez B, Prats-Mari L, Unfried JP, Fortes P. LncRNAs in the Type I Interferon antiviral response. Int J Mol Sci. 2020;21(17):6447.","DOI":"10.3390\/ijms21176447"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Wu D, Yin Z, Ji Y, Li L, Li Y, Meng F, Ren X, Xu M. Identification of novel autophagy-related lncRNAs associated with a poor prognosis of colon adenocarcinoma through bioinformatics analysis. Sci Rep. 2021;11(1):8069.","DOI":"10.1038\/s41598-021-87540-0"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Kimura T, Jiang S, Yoshida N, Sakamoto R, Nishizawa M. Interferon-alpha competing endogenous RNA network antagonizes microRNA-1270. Cell Mol Life Sci. 2015;72(14):2749-\u0080\u009361.","DOI":"10.1007\/s00018-015-1875-5"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Aboutalebi Vand Beilankouhi E, Sanaat Z, Hosseinpour Feizi MA, Mehdizadeh A, Safaralizadeh R. Investigation of circulating miR-182-3p, miR -382-3p and miR -93, miR -142-3p involved in tamoxifen resistance and sensitivity in luminal-subtype breast cancer patients: A case-\u0080\u0093control study. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2025;398(6):7505-\u0080\u009316.","DOI":"10.1007\/s00210-024-03770-9"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Au-Yeung N, Horvath CM. Transcriptional and chromatin regulation in interferon and innate antiviral gene expression. Cytokine Growth Factor Rev. 2018;44:11-\u0080\u00937.","DOI":"10.1016\/j.cytogfr.2018.10.003"},{"key":"81","unstructured":"Roos I, Leray E, Frascoli F, Casey R, Brown JW, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain. 2020;143(9):2742-\u0080\u009356."},{"key":"82","doi-asserted-by":"crossref","unstructured":"Xavier A, Campagna MP, Maltby VE, Kilpatrick T, Taylor BV, Butzkueven H, Ponsonby AL, Scott RJ, Jokubaitis VG, Lea RA, Lechner-Scott J. Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1162796"},{"key":"83","doi-asserted-by":"crossref","unstructured":"Hu X, Tian Z, Luo X, Chen C, Jiang G, Wang L, Peng R, Zhang H, Zhong M. Wetting behavior of gallium-based room temperature liquid metal (LM) on nanosecond-laser-structured metal surfaces. Surfaces Interf. 2022;32:102180.","DOI":"10.1016\/j.surfin.2022.102180"},{"key":"84","doi-asserted-by":"crossref","unstructured":"DeDiego ML, Martinez-Sobrido L, Topham DJ. Novel functions of IFI44L as a feedback regulator of host antiviral responses. J Virol. 2019;93(21):e01159-\u0080\u009319.","DOI":"10.1128\/JVI.01159-19"},{"key":"85","doi-asserted-by":"crossref","unstructured":"Banerjee S, Thompson WE, Chowdhury I. Emerging roles of microRNAs in the regulation of Toll-like receptor (TLR)-signaling. Front Biosci. 2021;26(4):771-\u0080\u009396.","DOI":"10.2741\/4917"},{"key":"86","doi-asserted-by":"crossref","unstructured":"Biondo C, Lentini G, Beninati C, Teti G. The dual role of innate immunity during influenza. Biomed J. 2019;42(1):8-\u0080\u009318.","DOI":"10.1016\/j.bj.2018.12.009"},{"key":"87","doi-asserted-by":"crossref","unstructured":"Yim M. The Role of Toll-like receptors in osteoclastogenesis. J Bone Metab. 2020;27(4):227-\u0080\u009335.","DOI":"10.11005\/jbm.2020.27.4.227"},{"key":"88","doi-asserted-by":"crossref","unstructured":"Matveeva OV, Chumakov PM. Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev Med Virol. 2018;28(6):e2008.","DOI":"10.1002\/rmv.2008"},{"key":"89","doi-asserted-by":"crossref","unstructured":"Askarian F, Wagner T, Johannessen M, Nizet V. Staphylococcus aureus modulation of innate immune responses through Toll-like (TLR), (NOD)-like (NLR) and C-type lectin (CLR) receptors. FEMS Microbiol Rev. 2018;42(5):656-\u0080\u009371.","DOI":"10.1093\/femsre\/fuy025"},{"key":"90","doi-asserted-by":"crossref","unstructured":"Ruangkiattikul N, Nerlich A, Abdissa K, Lienenklaus S, Suwandi A, Janze N, Laarmann K, Spanier J, Kalinke U, Weiss S, Goethe R. cGAS-STING-TBK1-IRF3\/7 induced interferon-\u00ce\u00b2 contributes to the clearing of non tuberculous mycobacterial infection in mice. Virulence. 2017;8(7):1303-\u0080\u009315.","DOI":"10.1080\/21505594.2017.1321191"},{"key":"91","doi-asserted-by":"crossref","unstructured":"Dhanwani R, Takahashi M, Sharma S. Cytosolic sensing of immuno-stimulatory DNA, the enemy within. Curr Opin Immunol. 2018;50:82-\u0080\u00937.","DOI":"10.1016\/j.coi.2017.11.004"},{"key":"92","doi-asserted-by":"crossref","unstructured":"Zhao M, Zhang Y, Yang X, Jin J, Shen Z, Feng X, Zou T, Deng L, Cheng D, Zhang X, Qin C, Niu C, Ye Z, Zhang X, He J, Hou C, Li G, Han G, Cheng Q, Wang Q, Wei L, Dong J, Zhang J. Myeloid neddylation targets IRF7 and promotes host innate immunity against RNA viruses. PLoS Pathog. 2021;17(9).","DOI":"10.1371\/journal.ppat.1009901"},{"key":"93","doi-asserted-by":"crossref","unstructured":"Larkin B, Ilyukha V, Sorokin M, Buzdin A, Vannier E, Poltorak A. Cutting edge: Activation of STING in T cells induces Type I IFN responses and cell death. J Immunol. 2017;199(2):397-\u0080\u0093402.","DOI":"10.4049\/jimmunol.1601999"},{"key":"94","doi-asserted-by":"crossref","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation-\u0080\u0094A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40-\u0080\u00937.","DOI":"10.1016\/j.ctrv.2017.11.007"},{"key":"95","doi-asserted-by":"crossref","unstructured":"Sittplangkoon C, Alameh MG, Weissman D, Lin PJC, Tam YK, Prompetchara E, Palaga T. mRNA vaccine with unmodified uridine induces robust Type I interferon-dependent anti-tumor immunity in a melanoma model. Front Immunol. 2022;13.","DOI":"10.3389\/fimmu.2022.983000"},{"key":"96","doi-asserted-by":"crossref","unstructured":"Padariya M, Sznarkowska A, Kote S, G\u00f3mez-Herranz M, Mikac S, Pilch M, Alfaro J, Fahraeus R, Hupp T, Kalathiya U. Functional interfaces, biological pathways, and regulations of interferon-related DNA damage resistance signature (IRDS) genes. Biomolecules. 2021;11(5):622.","DOI":"10.3390\/biom11050622"},{"key":"97","doi-asserted-by":"crossref","unstructured":"Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L. Cytosolic DNA sensing in organismal tumor control. Cancer Cell. 2018;34(3):361-\u0080\u009378.","DOI":"10.1016\/j.ccell.2018.05.013"},{"key":"98","doi-asserted-by":"crossref","unstructured":"Forero A, Ozarkar S, Li H, Lee CH, Hemann EA, Nadjsombati MS, Hendricks MR, So L, Green R, Roy CN, Sarkar SN, Von Moltke J, Anderson SK, Gale M, Savan R. Differential activation of the transcription factor IRF1 underlies the distinct immune responses elicited by Type I and Type III interferons. Immunity. 2019;51(3):451-\u0080\u0093464.e6.","DOI":"10.1016\/j.immuni.2019.07.007"},{"key":"99","doi-asserted-by":"crossref","unstructured":"Saikh KU, Morazzani EM, Piper AE, Bakken RR, Glass PJ. A small molecule inhibitor of MyD88 exhibits broad spectrum antiviral activity by up regulation of Type I interferon. Antiviral Res. 2020;181:104854.","DOI":"10.1016\/j.antiviral.2020.104854"},{"key":"100","doi-asserted-by":"crossref","unstructured":"Tang YY, Wang DC, Wang YQ, Huang AF, Xu WD. Emerging role of hypoxia-inducible factor-1\u00ce\u00b1 in inflammatory autoimmune diseases: A comprehensive review. Front Immunol. 2023;13.","DOI":"10.3389\/fimmu.2022.1073971"},{"key":"101","doi-asserted-by":"crossref","unstructured":"Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther. 2009;11(2):220.","DOI":"10.1186\/ar2598"},{"key":"102","doi-asserted-by":"crossref","unstructured":"Chen PM, Wilson PC, Shyer JA, Veselits M, Steach HR, Cui C, Moeckel G, Clark MR, Craft J. Kidney tissue hypoxia dictates T cell-\u0080\u0093mediated injury in murine lupus nephritis. Sci Transl Med. 2020;12(538):eaay1620.","DOI":"10.1126\/scitranslmed.aay1620"},{"key":"103","doi-asserted-by":"crossref","unstructured":"Soroush A, Dunn JF. A Hypoxia-inflammation cycle and multiple sclerosis: Mechanisms and therapeutic implications. Curr Treat Options Neurol. 2024;27(1):6.","DOI":"10.1007\/s11940-024-00816-4"},{"key":"104","doi-asserted-by":"crossref","unstructured":"Gong X, Yang SY, Wang ZY, Tang M. The role of hypoxic microenvironment in autoimmune diseases. Front Immunol. 2024;15.","DOI":"10.3389\/fimmu.2024.1435306"},{"key":"105","doi-asserted-by":"crossref","unstructured":"Xiao ZX, Miller JS, Zheng SG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev. 2021;20(2):102743.","DOI":"10.1016\/j.autrev.2020.102743"},{"key":"106","doi-asserted-by":"crossref","unstructured":"Luo Z, Tian M, Yang G, Tan Q, Chen Y, Li G, Zhang Q, Li Y, Wan P, Wu J. Hypoxia signaling in human health and diseases: Implications and prospects for therapeutics. Signal Transduct Target Ther. 2022;7(1):218.","DOI":"10.1038\/s41392-022-01080-1"},{"key":"107","doi-asserted-by":"crossref","unstructured":"Lequeux A, Noman MZ, Xiao M, Sauvage D, Van Moer K, Viry E, Bocci I, Hasmim M, Bosseler M, Berchem G, Janji B. Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. Cancer Lett. 2019;458:13-\u0080\u009320.","DOI":"10.1016\/j.canlet.2019.05.021"},{"key":"108","doi-asserted-by":"crossref","unstructured":"Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nat Rev Immunol. 2019;19(10):599-\u0080\u0093613.","DOI":"10.1038\/s41577-019-0194-8"},{"key":"109","unstructured":"Khodavirdipour A, Mehregan M, Zarini E. Molecular clock and autoimmune diseases; an approach to rheumatoid arthritis; A review. J Epigenet. 2019;1(2)."},{"key":"110","doi-asserted-by":"crossref","unstructured":"Theander E, Jonsson R, Sj\u00f6str\u00f6m B, Brokstad K, Olsson P, Henriksson G. Prediction of Sj\u00f6gren\u2019s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol. 2015;67(9):2427-\u0080\u009336.","DOI":"10.1002\/art.39214"},{"key":"111","doi-asserted-by":"crossref","unstructured":"Dobson R, Giovannoni G. Multiple sclerosis-\u0080\u0093A review. Eur J Neurol. 2019;26(1).","DOI":"10.1111\/ene.13819"},{"key":"112","doi-asserted-by":"crossref","unstructured":"Severa M, Rizzo F, Srinivasan S, Di Dario M, Giacomini E, Buscarinu MC, Cruciani M, Etna MP, Sandini S, Mechelli R, Farina A, Trivedi P, Hertzog PJ, Salvetti M, Farina C, Coccia EM. A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in multiple sclerosis. J Autoimmun. 2019;101:1-\u0080\u009316.","DOI":"10.1016\/j.jaut.2019.04.006"},{"key":"113","doi-asserted-by":"crossref","unstructured":"P\u00e9ter M, T\u00f6r\u00f6k W, Petrovics-Balog A, V\u00edgh L, V\u00e9csei L, Balogh G. Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain-\u0080\u0093Barr\u00e9 syndrome. Sci Rep. 2020;10(1):18380.","DOI":"10.1038\/s41598-020-75502-x"},{"key":"114","doi-asserted-by":"crossref","unstructured":"Lassmann H. Multiple sclerosis pathology. Cold Spring Harbor Persp Med. 2018;8(3):a028936.","DOI":"10.1101\/cshperspect.a028936"},{"key":"115","doi-asserted-by":"crossref","unstructured":"Crow YJ, Manel N. Aicardi-Gouti\u00e8res syndrome and the Type I interferonopathies. Nat Rev Immunol. 2015;15(7):429-\u0080\u009340.","DOI":"10.1038\/nri3850"},{"key":"116","doi-asserted-by":"crossref","unstructured":"Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology. 2017;56(10).","DOI":"10.1093\/rheumatology\/kew431"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/65b1c67808306428\/CRI-62673.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T20:43:12Z","timestamp":1779828192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,712794064b4c70af,65b1c67808306428.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2026062673","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}